Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines

Moderna to supply UK government with an extra 2 million vaccine doses

Moderna will supply the UK government with an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. “We appreciate the collaboration with the UK government as with many other governments and other key… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 Peer Hub combats vaccine avoidance amid pandemic

From March to April 2020, more than 50% of immunisation programmes around the world have reported significant disruptions to their vaccination services. Developed and delivered by The Geneva Learning Foundation, and supported by the Bill & Melinda Gates Foundation, the COVID-19 Peer Hub programme is connecting more than 4000 immunisation… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine 70% effective

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. Following the trial reaching the target for interim analysis, the independent Data… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Immunology / Virology & Vaccines

New study indicates Ebola vaccine safe, and produces robust immune response

Scientists from the University of Oxford, working as part of the EBOVAC2 EBL2001 study group, have announced the results of a Phase II trial of a replication-deficient adenovirus vaccine aimed at providing protection against the lethal Ebola virus. Writing in the journal Lancet: Infectious Diseases, they conclude that the two-dose… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford coronavirus vaccine produces strong immune response in older adults

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

European Medicines Agency begins rolling review of Moderna’s vaccine candidate

The European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of Moderna’s mRNA-1273 vaccine candidate against COVID-19. This follows confirmation of eligibility of mRNA-1273 for submission on October 14, 2020. On 16 November Moderna announced that the independent, US NIH-appointed Data Safety Monitoring Board (DSMB) for… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna announces supply agreement with UK government for COVID-19 vaccine

Moderna has announced a supply agreement with the UK government to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities. This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Interim clinical trial results of NIH-Moderna COVID-19 vaccine show 94% efficacy

The investigational NIH-Moderna COVID-19 vaccine mRNA-1273 has been found to be safe and effective at preventing symptomatic COVID-19 in adults. This is according to the interim results reviewed by an independent data and safety monitoring board (DSMB) overseeing the Phase III trial of the investigational COVID-19 vaccine mRNA-1273. The interim… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Johnson & Johnson starts second global phase III trial of Janssen COVID-19 vaccine candidate

The Janssen COVID-19 vaccine candidate leverages the company’s AdVac technology platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac technology platform has been used to vaccinate more than 110,000 people to date across… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Medicago and GSK start of Phase II/III clinical trials of adjuvanted COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are starting Phase II/III clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase I results, Medicago has decided to launch the Phase II/III clinical trial with GSK’s pandemic… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

CureVac’s COVID-19 vaccine candidate, suitable for standard fridge temperature logistics 

CureVac says its mRNA-based COVID-19 vaccine candidate, CVnCoV, remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature of +5°C (+41°F) and up to 24 hours as ready-to-use vaccine when stored at room temperature. “Transport and storage of vaccines requiring ultra-low temperature… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Life sciences report highlights implications of early COVID-19 vaccines data

FinnCap’s latest Rude Health Life Sciences Sector Report focuses on the implications of early COVID-19 vaccine data. This comes as Pfizer and BioNTech have announced their COVID-19 vaccine candidate has so far been found to be 90% effective in preventing COVID-19. Mark Brewer, Director of Research for finnCap, commented: "While the… Read More

#Business & Investment #Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Croda contract for Pfizer COVID-19 vaccine

Croda, the speciality chemical company has entered into an agreement with Pfizer to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract runs for five years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

It’s never been more important to talk about vaccines, says head of pharma organisation

Richard Torbett, Chief Executive, ABPI says vaccines are one of our best hopes for eradicating COVID-19 and why the ABPI is launching a campaign to highlight this. “COVID-19 has put shone a spotlight on the pharmaceutical industry like never before. Millions of people all over the world are living under… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Russia says Sputnik V vaccine against COVID-19 phase III clinical trials shows 92% efficacy

The National Research Center for Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced that the Sputnik V vaccine demonstrated high efficacy of 92%. The human adenoviral vectors vaccine against coronavirus was registered on the 11 August under the emergency use authorisation mechanism. The confirmation… Read More

#Covid-19 #Editor's Choice #News #Trending News